Mpox Vaccine
DrugVaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
NCT Number: NCT05522296
The purpose of this study is to assess the protection of smallpox preexposure vaccination against infection with mpox in real-world individuals with risk factors for mpox.
Looking for future studies?
Notify Me18 year and older
Male
Observational
Hospital Clínico San Borja Arriarán, Santiago, Santiago Metropolitan, Chile
A Target Trial Emulation study that tries to emulate the sequential specification of a target trial will be conducted measuring and controlling confounders when there is a common cause of vaccination and outcome event.
Participants will be provided with a Quick response (QR) code to access the RedCap study platform, which will guide them to the enrolment process. If the participant accepts and meets all the inclusion and none of the exclusion criteria, they will be directed to a baseline survey to self-collect sociodemographic data and information regarding risk factors, sexual behaviour, vaccination, and exposure to mpox.
Newly vaccinated participants will be matched 1:1 to unvaccinated controls. The matching will be performed based on the site of recruitment, and self-reported baseline sexual health and practices. Vaccinated and unvaccinated participants will be matched on variables associated with the probability of infection.
Follow-up will include regular surveys every month from the index date (i.e., enrolment date in the unvaccinated group, or vaccination date for the vaccinated group), to collect data on change on risk factors, sexual behaviour in the past month, vaccination status, and exposure to mpox. The participant will be asked to self-report if they develop symptoms suggestive of mpox, and the study platform will direct them to a specific mpox infection survey.
For each participant, follow-up will end at the earliest of the following events: mpox infection, voluntary withdraw, or the end of the study period. A health record review will be conducted to corroborate the diagnosis of new cases and to provide validity to the self-report.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
Time frame: From 14 days after the index date to twelve months after the index date
Mpox PCR positivity in participants with mpox infection symptoms
Time frame: From immediately after the index date to twelve months after the index date
Mpox PCR positivity in participants with mpox infection symptoms
Time frame: From 14 days after the index date to twelve months after the index date
Time from onset to resolution of general symptoms in participants with PCR-confirmed mpox infection (in days).
Time frame: From 14 days after the index date to twelve months after the index date
Number of mpox lesions (lesions count)
Time frame: From 14 days after the index date to twelve months after the index date
Time from onset to resolution of skin rash in participants with PCR-confirmed
Time frame: From 14 days after the index date to twelve months after the index date
Requirement of medical treatment (yes/no)
Time frame: From 14 days after the index date to twelve months after the index date
Requirement of hospital admission (yes/no)
Time frame: From 14 days after the index date to twelve months after the index date
Residual scarring after mpox (yes/no)
Time frame: One month after vaccination
Description of systemic and skin reactions
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Other
Break-through Infection Following Mpox vaccinatIon: Target Trial Emulation
Acronym: REMAIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05995275
Animal Diseases, DNA Virus Infections
Bradford, United Kingdom
View Trial DetailsNCT06136117
Animal Diseases, DNA Virus Infections
Tunda, Maniema Province, Democratic Republic of the Congo
View Trial DetailsNCT07499739
Animal Diseases, DNA Virus Infections
Kinshasa, Democratic Republic of the Congo
View Trial DetailsNCT07634081
Animal Diseases, DNA Virus Infections
Bukavu, Democratic Republic of the Congo
View Trial Details